IMPAACT 2001 STUDY Mhembere TP B Pharm Hons MPH GLOBAL TB BURDEN In 2015 there were an estimated 104 million new incident TB cases worldwide of which 59 million 56 were ID: 780464
Download The PPT/PDF document "A Phase I/II Trial of the Pharmacokineti..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection
IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)
Slide2GLOBAL TB BURDENIn 2015, there were an estimated 10.4 million new (incident) TB
cases worldwide, of which 5.9 million (56%) were among men, 3.5 million (34%) among women and 1.0 million (10%) among children. People living with HIV accounted for 1.2 million (11%) of all new TB cases in 2015.
2
Slide3LATENT TBLatent Tuberculosis Infection (LTBI)
is defined as a state of persistent immune response to Mycobacterium tuberculosis without clinically-manifested evidence of active TB disease2016 WHO Global TB Report
3
Slide4LATENT TB4
Slide5RISK FACTORS FOR DEVELOPING TB DISEASE FROM LTBI Risk factors for developing TB disease from LTBI include: •HIV infection •Infection with TB bacteria in the last 2 years •Children under 5years •Diabetes mellitus •Immune suppression
•Previous incomplete treatment for TB in the past5
Slide6LATENT TB & PREGNANCY Physiological changes during pregnancy
and the postpartum period may increase risk of LTBI reactivation Prevention of active TB in mother = prevention of TB in children
Negative sequalae on maternal-child
health
Increased
maternal and infant
mortality
Adverse
pregnancy outcomes (LBW,
SGA)
Infant
TB, increased maternal-infant HIV transmission
Singh
CID 2007; Zenner AJRCCM 2011 Gomes Thorax 2011; Anderson Clin Pharmacokinet 2005; Wadelius Clin Pharmacokinet 1997; Jana NEJM 1999; Chih H-C BJOG 2010; Khan AIDS 2001; Pillay Lancet ID 2000; Gupta CID 2007; Gupta JID 2011;
6
Slide7LATENT TB REACTIVATION PREVENTIONWHO:6-month isoniazid
9-month isoniazid3-month regimen of weekly rifapentine plus isoniazid 3–4 months isoniazid plus rifampicin,
3–4 months rifampicin alone.
Zimbabwe National TB Guidelines 2016: 6-month isoniazid
7
Slide8LATENT TB TREATMENT: INH & RPT TB Trials Consortium (TBTC) Study
26/ ACTG 5259: 3mo of directly observed once-weekly rifapentine (RPT) (900mg) plus INH (900mg) (3HP) VS 9mo of self-administered daily INH (300mg) (9H) 3HP (3mo Rifapentine + Isoniazid) was as effective as
standard 9H regimen and was associated with
a higher completion rate
(82% versus 69%) and
less drug-related hepatotoxicity (0.4% versus 2.7
%).
3HP regimen better
tolerated in HIV-1- infected
participants
compared to HIV-1-uninfected participants.
8
Slide9LATENT TB TREATMENT: INH & RPT 2.TB
Trials Consortium (TBTC) Study 26 [Paediatric Cohort]: Trial in children and adolescents to assess safety and efficacy of 3HP versus 9H regimen. 3HP resulted in higher adherence rates (88% in 3HP vs81% in 9H
).
Importantly,
neither arm exhibited any hepatotoxicity
, Grade 4 adverse events or treatment-attributed deaths.
0 of the children in the 3HP arm developed active TB versus 3 (0.74%) of the children in the 9H arm.
9
Slide10IMPAACT 2001 QUESTION Rifapentine + Isoniazid 3months to prevent LTB reactivation:
i) How do pregnancy induced physiological changes affect metabolism, function and disposition ?ii) Is it safe in pregnancy ?iii)
I
s it safe during breastfeeding?
10
Slide11STUDY DESIGN Prospective, open-label,
multi- centre study HIV-1-infected and HIV-1-uninfected pregnant women with latent TB and their infants, enrolled in two cohorts based on gestation:
• Cohort 1: Enrolled in second trimester
(14
to <28 weeks)
• Cohort 2: Enrolled in third trimester (28 to ≤34 weeks)
82
pregnant women (and their infants) will be enrolled to yield a minimum of 25
evaluable women
in each
cohort
12
DOT
once-weekly doses of RPT (900mg) and INH (900mg) taken
with pyridoxine 50mg.
Each woman
will be followed through pregnancy
up to 24
weeks postpartum. 11
Slide1212
Slide13STUDY DRUGS Rifapentine (RPT) 900 mg (6 x 150 mg tablets) under directly observed therapy once-weekly for 12 weeks
Isoniazid (INH) 900 mg (3 x 300 mg tablets) under directly observed therapy once-weekly for 12 weeksPyridoxine 50mg once-weekly in conjunction with RPT+ INH13
Slide14PRIMARY OBJECTIVESTo estimate the population pharmacokinetics (PK) (CL/F, absorption, volume of distribution) of RPT and its desacetyl-rifapentine metabolite (desRPT) among pregnant women during the second trimester and third trimester who are receiving once-weekly RPT
To estimate the incidence of serious adverse events (SAEs) related to RPT + INH dosed once weekly for 12 weeks in pregnant women. To describe the infant safety outcomes among infants born to women receiving once-weekly RPT + INH.14
Slide15INCLUSION CRITERIA≥ 18 years,
Informed ConsentPregnancy with estimated gestational age ≥ 14 through ≤ 34 weeks.
Has at least one of the following risk factors for L
TB
:
(1)Participant
is a household
contact of known active pulmonary TB patient
(2)
Confirmed
HIV-1 infection
and positive Tuberculin Skin Test
15
Slide16EXCLUSION CRITERIAEvidence of confirmed or probable active TB disease
History of active TB in the past 2 yearsPrevious treatment for LTBI. Documentation of multi-drug resistant (MDR) or extensively drug resistant (XDR) TB (history/ contact)Known major fetal abnormality as detected on
ultrasound
16
Slide17SUMMARYTB disease is problematic globally and locally Pregnant/ postpartum
women with LTBI have ↑risk of developing TB Standard LTBI regimen of 6-9 months daily INH has low completion rates and some hepatotoxicity R
egimen of 3
months weekly
INH + RPT has shown
↑
completion
rates, ↓hepatotoxicity and safety
in HIV-1-infected
populations.
IMPAACT 2001 will provide
data needed to extend use
of 3
months weekly
Isoniazid+ Rifapentine to
pregnant
women
.
17
Slide18CURRENT STUDY STATUS7 International Sites participating. Harare Site to enrol
10 of 82 participants.Approval from all IRBs receivedProtocol registered with sponsorReceived activation from protocol team (02 May 17)18
Slide19ACKNOWLEDGEMENTSIMPAACT NETWORKUZ-UCSF SITE LEADERSHIP
HARARE FAMILY CARE CRS STAFFIMPAACT COMMUNITY ADVISORY BOARD19
Slide2020